Clinical Trial

Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-17; most recent amendment 2025-05-23.
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06882811
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions Sepsis
Enrollment 180 participants
Start Date 2025-05-22
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-25